{"url_path":"/sec/vvos/8-k/2026-06-25/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 Entry into a Material Definitive Agreement.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-25","source_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-030190-index.html","accession_number":"0001493152-26-030190","cik":"0001716166","ticker":"VVOS","issuer_name":"Vivos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-030190-index.html","primary_entity_key":"0001716166","primary_entity_name":"Vivos Therapeutics, Inc."},"word_count":162,"has_tables":true,"body_markdown":"**Item\n1.01 Entry into a Material Definitive Agreement.**\n\n \n\nAs\npreviously announced, Vivos Therapeutics, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”)\nwith Streeterville Capital, LLC, a Utah limited liability company (“Streeterville”), on June 5, 2026. Pursuant to the Exchange\nAgreement, Streeterville agreed to exchange a portion of the outstanding indebtedness owed by the Company for shares of the Company’s\npreferred stock and common stock.\n\n \n\nOn\nJune 18, 2026, the Company entered into a letter agreement with Streeterville amending the Exchange Agreement (the “Letter Agreement”),\nto extend the outside date by which the Company must complete a qualifying financing of at least $2,600,000 from June 15, 2026, to August\n31, 2026.\n\n \n\nThe\nforegoing description of the Exchange Agreement or the Letter Agreement does not purport to be complete and is qualified in its entirety\nby reference to the full text of such agreements, a copy of which is filed as Exhibits 10.1 and 10.2 hereto and incorporated herein by\nreference."}